Merger activity decreased last week with six new deals announced and four deals closing. We had a new deal with the highest premium I have ever seen since we started tracking this data. The acquisition of Tobira Therapeutics (TBRA) by Allergan (AGN) discussed below led to a jump of 721% in the stock of Tobira because just the cash portion of the deal at $28.35 was several times higher than the Tobira’s closing price of $4.74 the previous day. The deal also includes a Contingent Value Right (CVR) that could pay up to $49.84 per share if certain conditions are met. Given the complexity of the deal, we have entered it as a “Special Conditions” deal and will publish a follow-up article explaining how we came up with our rough estimate of $40.89 per share for the deal.
The acquisition of Hutchinson Technology (HTCH) by TDK appears to be nearing completion and you can read a blow-by-blow account of my experience with this deal in a new article called A Wild Ride With Hutchinson Technology And The Case For Diversified Portfolios that is a follow-up to our earlier article Collecting Pennies in Front of a Bulldozer.
You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours.
Deal Statistics:
New Deals: